To summarize the last article: GLP-1 medications are reshaping modern medicine because they target the gut-brain-metabolic axis that drives most chronic disease - not just weight loss, but cardiovascular disease, heart failure, kidney disease, neurodegeneration, fatty liver, and systemic inflammation
Supplementation Reduced food intake means reduced micronutrient intake
These improvements are likely to increase patient compliance and improve their overall quality of life
More recent research, however, has shown that C-peptide is biologically active and may play a meaningful role in glucose regulation and diabetes-related complications
Several small observational studies have documented improvements in IBS-related symptoms among patients using semaglutide, including reduced bloating, decreased constipation episodes, and lower abdominal pain scores